Isofagomine In Vivo Effects in a Neuronopathic Gaucher Disease Mouse
Open Access
- 20 April 2011
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 6 (4) , e19037
Abstract
The pharmacological chaperone, isofagomine (IFG), enhances acid β-glucosidase (GCase) function by altering folding, trafficking, and activity in wild-type and Gaucher disease fibroblasts. The in vivo effects of IFG on GCase activity, its substrate levels, and phenotype were evaluated using a neuronopathic Gaucher disease mouse model, 4L;C* (V394L/V394L + saposin C-/-) that has CNS accumulation of glucosylceramide (GC) and glucosylsphingosine (GS) as well as progressive neurological deterioration. IFG administration to 4L;C* mice at 20 or 600 mg/kg/day resulted in life span extensions of 10 or 20 days, respectively, and increases in GCase activity and protein levels in the brain and visceral tissues. Cerebral cortical GC and GS levels showed no significant reductions with IFG treatment. Increases of GC or GS levels were detected in the visceral tissues of IFG treated (600 mg/kg/day) mice. The attenuations of brain proinflammatory responses in the treated mice were evidenced by reductions in astrogliosis and microglial cell activation, and decreased p38 phosphorylation and TNFα levels. Terminally, axonal degeneration was present in the brain and spinal cord from untreated and treated 4L;C* mice. These data demonstrate that IFG exerts in vivo effects by enhancing V394L GCase protein and activity levels, and in mediating suppression of proinflammation, which led to delayed onset of neurological disease and extension of the life span of 4L;C* mice. However, this was not correlated with a reduction in the accumulation of lipid substrates.Keywords
This publication has 39 references indexed in Scilit:
- Type 2 Gaucher disease: Phenotypic variation and genotypic heterogeneityBlood Cells, Molecules, and Diseases, 2011
- Improved management of lysosomal glucosylceramide levels in a mouse model of type 1 Gaucher disease using enzyme and substrate reduction therapyJournal of Inherited Metabolic Disease, 2010
- Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficitsHuman Molecular Genetics, 2010
- Specific saposin C deficiency: CNS impairment and acid -glucosidase effects in the mouseHuman Molecular Genetics, 2009
- Effects of treatments on inflammatory and apoptotic markers in the CNS of mice with globoid cell leukodystrophyBrain Research, 2009
- Acid β-Glucosidase 1 Counteracts p38δ-dependent Induction of Interleukin-6Journal of Biological Chemistry, 2009
- Involvement of Acid β-Glucosidase 1 in the Salvage Pathway of Ceramide FormationJournal of Biological Chemistry, 2009
- Effects of pH and Iminosugar Pharmacological Chaperones on Lysosomal Glycosidase Structure and StabilityBiochemistry, 2009
- Dependence of reversibility and progression of mouse neuronopathic Gaucher disease on acid β-glucosidase residual activity levelsMolecular Genetics and Metabolism, 2008
- The iminosugar isofagomine increases the activity of N370S mutant acid β-glucosidase in Gaucher fibroblasts by several mechanismsProceedings of the National Academy of Sciences, 2006